SPRO - Spero Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
SPRO price evolution
SPRO
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $63.53 | $82.27 | $76.33 | |
| Short term investments | ||||
| Net receivables | $53.28 | $79.08 | $77.43 | $97.29 |
| Inventory | ||||
| Total current assets | $131.63 | $122.22 | $140.15 | $131.21 |
| Long term investments | ||||
| Property, plant & equipment | $3.38 | $3.64 | $3.9 | $4.16 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $27.66 | $27.55 | $51.18 | |
| Total investments | ||||
| Total assets | $135.16 | $149.88 | $167.7 | $182.39 |
| Current liabilities | ||||
| Accounts payable | $6.09 | $2.7 | $3.07 | $1.38 |
| Deferred revenue | $51.32 | $57.34 | $61.54 | |
| Short long term debt | $1.73 | $1.73 | $1.72 | |
| Total current liabilities | $49.1 | $45.63 | $41.82 | $37.15 |
| Long term debt | $3.21 | $3.52 | $3.83 | |
| Total noncurrent liabilities | $23.75 | $29.63 | $38.34 | |
| Total debt | $4.94 | $5.24 | $5.54 | |
| Total liabilities | $69.65 | $69.38 | $71.45 | $75.5 |
| Shareholders' equity | ||||
| Retained earnings | -$438.75 | -$421.6 | -$403.74 | -$391.07 |
| Other shareholder equity | ||||
| Total shareholder equity | $80.5 | $96.25 | $106.89 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $76.33 | $109.11 | $112.58 | $85.21 |
| Short term investments | $33.82 | $41.7 | ||
| Net receivables | $97.29 | $1.08 | $2.28 | $5.33 |
| Inventory | ||||
| Total current assets | $131.21 | $113.57 | $157.87 | $139.15 |
| Long term investments | ||||
| Property, plant & equipment | $4.16 | $5.49 | $7.56 | $8.78 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $51.18 | $11.23 | $13.2 | $14.31 |
| Total investments | $33.82 | $41.7 | ||
| Total assets | $182.39 | $124.8 | $171.07 | $153.45 |
| Current liabilities | ||||
| Accounts payable | $1.38 | $0.62 | $1.1 | $1.16 |
| Deferred revenue | $61.54 | $32.53 | $10.64 | |
| Short long term debt | $1.72 | $1.69 | $1.36 | $0.95 |
| Total current liabilities | $37.15 | $21.65 | $18.67 | $14.34 |
| Long term debt | $3.83 | $4.96 | $5.97 | $6.89 |
| Total noncurrent liabilities | $38.34 | $27.22 | $64.11 | $7.07 |
| Total debt | $5.54 | $6.65 | $7.33 | $7.84 |
| Total liabilities | $75.5 | $48.87 | $82.78 | $21.41 |
| Shareholders' equity | ||||
| Retained earnings | -$391.07 | -$413.88 | -$367.46 | -$277.71 |
| Other shareholder equity | -$0 | -$0.01 | ||
| Total shareholder equity | $106.89 | $75.93 | $88.29 | $132.04 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $10.2 | $9.27 | $73.52 | |
| Cost of revenue | ||||
| Gross Profit | $10.2 | $9.27 | $73.52 | |
| Operating activities | ||||
| Research & development | $23.73 | $17.33 | $16.56 | |
| Selling, general & administrative | $5.53 | $5.92 | $6.43 | |
| Total operating expenses | $29.26 | $23.25 | $22.99 | |
| Operating income | -$19.06 | -$13.98 | $50.53 | |
| Income from continuing operations | ||||
| EBIT | -$17.86 | -$12.67 | $51.58 | |
| Income tax expense | $0.39 | |||
| Interest expense | ||||
| Net income | ||||
| Net income | -$17.86 | -$12.67 | $51.19 | |
| Income (for common shares) | -$17.86 | -$12.67 | $51.19 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $103.78 | $53.51 | $18.26 | $9.33 |
| Cost of revenue | ||||
| Gross Profit | $103.78 | $53.51 | $18.26 | $9.33 |
| Operating activities | ||||
| Research & development | $51.44 | $47.59 | $64.53 | $67 |
| Selling, general & administrative | $25.55 | $36.48 | $41.7 | $21.44 |
| Total operating expenses | $82.3 | $95.71 | $106.23 | $88.44 |
| Operating income | $21.48 | -$42.2 | -$87.97 | -$79.11 |
| Income from continuing operations | ||||
| EBIT | $25.4 | -$43.81 | -$87.82 | -$78.28 |
| Income tax expense | $2.6 | |||
| Interest expense | $2.6 | $1.94 | ||
| Net income | ||||
| Net income | $22.81 | -$46.41 | -$89.76 | -$78.28 |
| Income (for common shares) | $22.81 | -$46.41 | -$89.76 | -$78.28 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$17.86 | -$12.67 | $51.19 | |
| Operating activities | ||||
| Depreciation | $0 | $0.04 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.11 | $2.02 | $2 | |
| Total cash flows from operations | -$18.74 | $5.94 | -$17.49 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0 | |||
| Net borrowings | ||||
| Total cash flows from financing | $0 | |||
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$0.04 | -$18.74 | $5.94 | -$17.49 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $22.81 | -$46.41 | -$89.76 | -$78.28 |
| Operating activities | ||||
| Depreciation | $0.37 | $0.87 | $0.65 | $0.76 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $7.93 | $9.12 | $9.43 | $4.89 |
| Total cash flows from operations | -$32.99 | -$7.73 | -$64.35 | -$85.87 |
| Investing activities | ||||
| Capital expenditures | -$0.16 | |||
| Investments | $33.81 | $7.63 | $10.63 | |
| Total cash flows from investing | $33.81 | $7.67 | $10.47 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.22 | $24.93 | $36.82 | $80.85 |
| Net borrowings | -$54.48 | |||
| Total cash flows from financing | $0.22 | -$29.55 | $84.05 | $130.88 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$32.77 | -$3.48 | $27.38 | $55.48 |
News
|
MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease
Zacks · via Yahoo Finance
19 Dec 2024
|
|
KRYS Stock Down on Initial Clinical Updates on KB407 & KB408
Zacks · via Yahoo Finance
14 Dec 2024
|
|
SNY's Tolebrutinib Gets FDA Breakthrough Therapy Tag for nrSPMS
Zacks · via Yahoo Finance
13 Dec 2024
|
|
Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up
Zacks · via Yahoo Finance
9 Dec 2024
|
|
AstraZeneca's Imfinzi Gets FDA Nod for Expanded Use in SCLC
Zacks · via Yahoo Finance
6 Dec 2024
|
|
RZLT Stock Rises on FDA's Orphan Designation for Rare Disease Drug
Zacks · via Yahoo Finance
4 Dec 2024
|
|
ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada
Zacks · via Yahoo Finance
4 Dec 2024
|
|
ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada
Zacks
2 Dec 2024
|
|
Mirum Shares Surge More Than 90% in 6 Months: Here's Why
Zacks · via Yahoo Finance
29 Nov 2024
|
|
GSK Gets EC Nod for Liquid Version of Meningococcal Vaccine Menveo
Zacks · via Yahoo Finance
29 Nov 2024
|
Fundamentals
| Market cap | $45.14M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 54.31M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.71 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.68 |
| Quick ratio | N/A |